Trial Profile

A Phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osimertinib (Primary) ; Tepotinib (Primary) ; Antineoplastics; Gefitinib
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms INSIGHT 2
Sponsors EMD Serono Research & Development Institute; Merck KGaA

23 Jul 2024 Planned End Date changed from 27 May 2024 to 31 Oct 2025.
29 Nov 2023 Planned End Date changed from 17 Sep 2023 to 27 May 2024.
24 Oct 2023 Results assessing Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC in INSIGHT 1 & INSIGHT 2 studies, presented at the 48th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com